Linical Co., Ltd.

TSE:2183 Stock Report

Market Cap: JP¥7.6b

Linical Past Earnings Performance

Past criteria checks 0/6

Linical has been growing earnings at an average annual rate of 2.3%, while the Life Sciences industry saw earnings growing at 24.8% annually. Revenues have been growing at an average rate of 3.7% per year.

Key information

2.3%

Earnings growth rate

2.3%

EPS growth rate

Life Sciences Industry Growth32.0%
Revenue growth rate3.7%
Return on equity-1.6%
Net Margin-1.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

There May Be Some Bright Spots In Linical's (TSE:2183) Earnings

May 22
There May Be Some Bright Spots In Linical's (TSE:2183) Earnings

Recent updates

Linical's (TSE:2183) Shareholders Will Receive A Bigger Dividend Than Last Year

Dec 01
Linical's (TSE:2183) Shareholders Will Receive A Bigger Dividend Than Last Year

Linical's (TSE:2183) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 17
Linical's (TSE:2183) Shareholders Will Receive A Bigger Dividend Than Last Year

There May Be Some Bright Spots In Linical's (TSE:2183) Earnings

May 22
There May Be Some Bright Spots In Linical's (TSE:2183) Earnings

Some Linical Co., Ltd. (TSE:2183) Shareholders Look For Exit As Shares Take 26% Pounding

Mar 08
Some Linical Co., Ltd. (TSE:2183) Shareholders Look For Exit As Shares Take 26% Pounding

Linical (TSE:2183) Is Paying Out A Larger Dividend Than Last Year

Feb 26
Linical (TSE:2183) Is Paying Out A Larger Dividend Than Last Year

Revenue & Expenses Breakdown

How Linical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:2183 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2411,669-1202,6490
30 Jun 2412,1512532,6600
31 Mar 2412,3073382,7050
31 Dec 2312,5186802,5900
30 Sep 2312,6607142,6050
30 Jun 2312,7309312,5880
31 Mar 2312,5161,0042,5090
31 Dec 2212,1888432,5930
30 Sep 2211,9531,0062,4840
30 Jun 2211,6397992,3760
31 Mar 2211,5557902,1860
31 Dec 2111,3609062,0860
30 Sep 2110,8208042,0100
30 Jun 2110,6398051,9590
31 Mar 2110,2795392,0160
31 Dec 2010,2622412,0590
30 Sep 2010,5272392,0800
30 Jun 2010,6792682,1800
31 Mar 2010,9354822,1690
31 Dec 1910,9445082,0650
30 Sep 1911,0904092,0570
30 Jun 1911,2345412,0320
31 Mar 1911,3135682,1890
31 Dec 1810,9758532,2540
30 Sep 1810,4061,1472,0570
30 Jun 189,7361,1771,8420
31 Mar 189,1131,2951,5110
31 Dec 178,8701,2811,5080
30 Sep 178,6451,2371,4900
30 Jun 178,5411,3811,4440
31 Mar 178,3551,4471,3890
31 Dec 168,1311,3751,4410
30 Sep 167,9161,3311,4250
30 Jun 167,8911,3681,3820
31 Mar 167,6661,3301,3420
31 Dec 157,4201,1541,3100
30 Sep 156,6441,0151,1320
30 Jun 155,5495799910
31 Mar 154,8724378620
31 Dec 144,2314657750
30 Sep 144,0224297550
30 Jun 143,9094457460
31 Mar 143,7214497140
31 Dec 133,6924737230

Quality Earnings: 2183 is currently unprofitable.

Growing Profit Margin: 2183 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 2183 is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.

Accelerating Growth: Unable to compare 2183's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2183 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (1.4%).

Return on Equity

High ROE: 2183 has a negative Return on Equity (-1.63%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 23:40
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Linical Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Masao YoshidaIchiyoshi Research Institute Inc.
Michael NewmanMacquarie Research
Yasunori HiromotoMarusan Securities Co. Ltd.